Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy



Status:Archived
Conditions:Arthritis, Rheumatoid Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:Any
Updated:7/1/2011

Use our guide to learn which trials are right for you!

CSP #551 - Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy


Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints leading to joint
destruction, with significant long-term morbidity and mortality. Early treatment of RA
patients with disease-modifying antirheumatic drugs (DMARDs) significantly decreases these
complications. Methotrexate (MTX) is an excellent, economical first-line DMARD used to
treat a majority of RA patients. While most patients respond well to MTX, many continue to
have active disease. Therefore, understanding how to best treat RA patients with active
disease despite MTX therapy is critically important. Although a number of therapies with
significantly different economic implications have been shown to be effective when added to
MTX, no trial has directly compared active therapies. This study will compare therapeutic
strategies using two regimens with proven efficacy when added to MTX therapy; a)
hydroxychloroquine and sulfasalazine (cost ~ $1000 per year); b) the tumor necrosis factor
inhibitor, etanercept (cost ~ $12,000 per year).

We propose a bi-national multi-center randomized, double-blind equivalency trial comparing
(A) the strategy of initially adding hydroxychloroquine and sulfasalazine to MTX in patients
with active disease despite MTX, with a switch at 24 weeks to etanercept in nonresponders to
(B) a strategy of adding etanercept to MTX, with a switch to hydroxychloroquine and
sulfasalazine in nonresponders at 24 weeks. If we find that the strategy of first adding
hydroxychloroquine and sulfasalazine to MTX identifies a subset of responsive patients and
that there is no harm to nonresponders because of early rescue with etanercept, then this
less expensive option should become the standard treatment for MTX resistant patients.

Four hundred and fifty RA patients with active disease despite treatment with MTX as
indicated by a Disease Activity Score with 28 joints (DAS28) of >4.4 units will be
randomized. A DAS improvement of <1.2 (validated as clinically significant) at 24 weeks
will be used to identify early nonresponder who will switch therapy. Subjects with a DAS28
improvement of > 1.2 at 24 weeks will remain on their initial therapy. The primary
endpoint is the change of DAS 28 scores from baseline to 48 weeks. The secondary endpoint
is comparison of radiographic progression of disease at 48 weeks, as measured by the change
in Sharp score. Economic and functional outcomes will be assessed and a serum and DNA bank
will be established to evaluate potential biomarkers predictive of treatment
response/toxicity and disease progression. This trial will recruit 450 subjects over 40
months. At the end of the 48 week blinded active therapy portion of the trial, the blind
will be broken and data will be collected in an open fashion until all 450 patients have
completed the 48 week portion of the trial.


The main objective of this proposal is to compare two successful treatment strategies that
have significantly different economic implications head-to-head in patients with rheumatoid
arthritis who have active disease despite methotrexate therapy.

Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints leading to joint
destruction, with significant long-term morbidity and mortality. Early treatment of RA
patients with disease-modifying antirheumatic drugs (DMARDs) significantly decreases these
complications. Methotrexate (MTX) is an excellent, economical first-line DMARD used to treat
a majority of RA patients. While most patients respond well to MTX, many continue to have
active disease. Therefore, understanding how to best treat RA patients with active disease
despite MTX therapy is critically important. Although a number of therapies with
significantly different economic implications have been shown to be effective when added to
MTX, no trial has directly compared active therapies. This study will compare therapeutic
strategies using two regimens with proven efficacy when added to MTX therapy; a)
hydroxychloroquine and sulfasalazine (cost ~ $1000 per year); b) the tumor necrosis factor
inhibitor, etanercept (cost ~ $12,000 per year).

We propose a bi-national multi-center randomized, double-blind equivalency trial comparing
(A) the strategy of initially adding hydroxychloroquine and sulfasalazine to MTX in patients
with active disease despite MTX, with a switch at 24 weeks to etanercept in nonresponders to
(B) a strategy of adding etanercept to MTX, with a switch to hydroxychloroquine and
sulfasalazine in nonresponders at 24 weeks. If we find that the strategy of first adding
hydroxychloroquine and sulfasalazine to MTX identifies a subset of responsive patients and
that there is no harm to nonresponders because of early rescue with etanercept, then this
less expensive option should become the standard treatment for MTX resistant patients.

Four hundred and fifty RA patients with active disease despite treatment with MTX as
indicated by a Disease Activity Score with 28 joints (DAS28) of greater than or equal to 4.4
units will be randomized. A DAS improvement of greater than or equal to 1.2 (validated as
clinically significant) at 24 weeks will be used to identify early nonresponder who will
switch therapy. Subjects with a DAS28 improvement of > 1.2 at 24 weeks will remain on their
initial therapy. The primary endpoint is the change of DAS 28 scores from baseline to 48
weeks. The secondary endpoint is comparison of radiographic progression of disease at 48
weeks, as measured by the change in Sharp score. Economic and functional outcomes will be
assessed and a serum and DNA bank will be established to evaluate potential biomarkers
predictive of treatment response/toxicity and disease progression. This trial will recruit
450 subjects over 40 months. At the end of the 48 week blinded active therapy portion of the
trial, the blind will be broken and data will be collected in an open fashion until all 450
patients have completed the 48 week portion of the trial.


We found this trial at
30
sites
?
mi
from
White River Junction, VT
Click here to add this to my saved trials
13000 Bruce B Downs Blvd # T72
Tampa, Florida 33612
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Bismarck, North Dakota 58501
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
Brockton, Massachusetts 02301
?
mi
from
Brockton, MA
Click here to add this to my saved trials
Charleston, South Carolina 29401
?
mi
from
Charleston, SC
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Dallas, Texas 75216
?
mi
from
Dallas, TX
Click here to add this to my saved trials
100 North Academy Avenue
Danville, Pennsylvania 17822
570-271-6211
Geisinger Medical Center Since 1915, Geisinger Medical Center has been known as the region’s resource...
?
mi
from
Danville, PA
Click here to add this to my saved trials
?
mi
from
Duluth, MN
Click here to add this to my saved trials
Fargo, North Dakota 58102
?
mi
from
Fargo, ND
Click here to add this to my saved trials
Lincoln, Nebraska 68506
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
Loma Linda, California 92357
?
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Long Beach, California 90822
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
Minneapolis, Minnesota 55417
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Omaha, Nebraska 68105
?
mi
from
Omaha, NE
Click here to add this to my saved trials
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19107
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15240
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Portland, Oregon 97201
?
mi
from
Portland, OR
Click here to add this to my saved trials
Rapid City, South Dakota 57701
?
mi
from
Rapid City, SD
Click here to add this to my saved trials
200 First Street SW
Rochester, Minnesota 55905
507-284-2511
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
?
mi
from
Rochester, MN
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Francisco, California 94121
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Santa Maria, California 93454
?
mi
from
Santa Maria, CA
Click here to add this to my saved trials
Sepulveda, California 91343
?
mi
from
Sepulveda, CA
Click here to add this to my saved trials
Sioux Falls, South Dakota 57117
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
St Louis, Missouri 63106
?
mi
from
St Louis, MO
Click here to add this to my saved trials
State College, Pennsylvania 16801
?
mi
from
State College, PA
Click here to add this to my saved trials
Washington D.C., Washington DC 20422
?
mi
from
Washington D.C., DC
Click here to add this to my saved trials
Wyoming Valley, Pennsylvania 18711
?
mi
from
Wyoming Valley, PA
Click here to add this to my saved trials